Skeptics have pointed to the fact that the Biotechnology Value Fund (BVF) provided Genaera with several million dollars of new funding in May in return for about a 10.5% equity stake in the company, but sharply reduced its holdings of Genaera shortly after the positive trial results had been released.
LOL. The skeptics need a class in Investing 101. BVF took some cash off the table and is still sitting on shares and warrants.
Market Data 
Markets 
AI
